Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2016 · 10-Q
Revenue$8.79M$8.79M+11.5% vs Q3 2015 Net Income$106.17K$106.17K−16.1% vs Q3 2015 EPS Diluted$0.01$0.01±0.0% vs Q3 2015 Operating Income$130,132−52.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$265,799−41.1% Margins · derivedOperating margin1.5%−2.0 pt vs Q3 2015
Net margin1.2%−0.4 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 3, 2016 · 34 d after period end